← Therapy pipeline
Investigational · Obesity development

Naperiglipron

LY3549492 · Eli Lilly

An oral small-molecule GLP-1 receptor agonist listed in Lilly’s obesity pipeline.

GLP-1
Obesity stagePhase 2Updated as of November 2026
SponsorEli Lilly
TargetsGLP-1
RouteOral tablet
DevelopmentObesity-specific
01 / Evidence

Results availability

No numerical results shown

No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.

02 / How it works

Mechanism at a glance

GLP-1GLP-1Targeted
GIPGIP—
GCGglucagon—
AMYamylin—
OTHOther targets—
Explore the hormone anatomy ↗
03 / Development

Obesity stage by formulation

Oral small moleculeOral tablet
Phase 2Phase 2; original obesity study completed; separate protocol terminated
Milestone → next

Latest: The original obesity Phase 2 study was completed in May 2026. A separate obesity/type 2 diabetes Phase 2 protocol was terminated for strategic business reasons after one participant enrolled; Lilly continues to list naperiglipron in its pipeline.

Next: Further sponsor clarification of obesity development; no numerical outcome is inferred from the terminated study.

04 / Study records

Clinical study records

Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.

Obesity and weight-management studies

Phase 2 studies2 records

Phase 2

Naperiglipron · obesity with type 2 diabetes

Weight management with type 2 diabetes
Study: TerminatedResults: Registry results posted; not yet summarized hereStatus reviewed November 2026

Separate Phase 2 study terminated for strategic business reasons after one participant enrolled. This trial-specific decision does not establish discontinuation of the whole candidate.

Phase 2

NCT06683508 · weight management

Weight management
Study: CompletedResults: No registry results posted yetStatus reviewed November 2026

Adults with obesity or overweight; registry study completed May 2026. Further candidate-development status is unclear.